2-chloro-6-(pyridin-2-yl)pyrazine | 868379-69-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloro-6-(pyridin-2-yl)pyrazine
• 英文别名: 2-Chloro-6-pyridin-2-ylpyrazine
• CAS: 868379-69-5
• 化学式: C₉H₆ClN₃
• 分子量: 191.62
• InChiKey: CIRAXCCUAYPYQV-UHFFFAOYSA-N

物化性质

• 沸点：
  314.9±37.0 °C(Predicted)
• 密度：
  1.309±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-thiophen-2-yl-pyridin-2-ylamine 、 2-chloro-6-(pyridin-2-yl)pyrazine 在 sodium hydride 、 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 为溶剂， 反应 0.33h， 生成 (6-pyridin-2-yl-pyrazin-2-yl)-(5-thiophen-2-yl-pyridin-2-yl)-amine dihydrochloride
  参考文献：
  名称：

  Polycyclic pyrazines as potassium ion channel modulators

  摘要：

  本发明提供了一类多环吡嗪，可作为钾离子通道调节剂。该发明的调节剂可用于治疗和诊断方法。

  公开号：

  US20050239800A1
• 作为产物：
  描述：

  2,6-二氯吡嗪 、 三正丁基2-吡啶基锌 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 反应 48.0h， 生成 2-chloro-6-(pyridin-2-yl)pyrazine
  参考文献：
  名称：

  Polycyclic pyrazines as potassium ion channel modulators

  摘要：

  本发明提供了一类多环吡嗪，可作为钾离子通道调节剂。该发明的调节剂可用于治疗和诊断方法。

  公开号：

  US20050239800A1

文献信息

• POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS
  申请人：Icagen, Inc.

  公开号：EP1742935A1

  公开（公告）日：2007-01-17
• US7642354B2
  申请人：——

  公开号：US7642354B2

  公开（公告）日：2010-01-05
• [EN] POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS<br/>[FR] PYRAZINES POLYCYCLIQUES TENANT LIEU DE MODULATEURS DU CANAL IONIQUE DU POTASSIUM
  申请人：ICAGEN INC

  公开号：WO2005121126A1

  公开（公告）日：2005-12-22

  The present invention provides a genus of polycyclic pyrazines of formula I (I) that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods; wherein A and B are independently substituted or unsubstituted 5- or 6-membered heterocycloalkyl, or substituted or unsubstituted 5- or 6- membered heteroaryl, W1 is formula II (II); W2 is -CH=, -NH-, -N=, -S-, or -O-; Z1 is formula III (III) or formula IV (IV); Z2 is -CH=, -NH-, -N=, -S-, or -O-; Y is a bond, -CH=N-NH-, -NH-CH2-, or -NR5-; s and t are independently integers from 1 to 4; R1, R2A, R2B and R3 are independently or unsubstituted alkyle, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl,, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R5 is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl,, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; wherein if s is greater than one, then each R1 is optionally different; wherein if t is greater than on, then each R3 is optionally different; wherein two R1 groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted ring; and wherein two R3 groups are optionally joined together with the atoms to which they are attached to form a susbtituted or unsubstituted ring.
• Polycyclic pyrazines as potassium ion channel modulators
  申请人：Wang Xiaodong

  公开号：US20050239800A1

  公开（公告）日：2005-10-27

  The present invention provides a genus of polycyclic pyrazines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.

  本发明提供了一类多环吡嗪，可作为钾离子通道调节剂。该发明的调节剂可用于治疗和诊断方法。
• [EN] CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE CYCLOHEXANE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DE LPA
  申请人：[en]CHIESI FARMACEUTICI S.P.A.

  公开号：WO2023118253A1

  公开（公告）日：2023-06-29

  The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.